Pykus Therapeutics, Inc. ("Pykus" or the "Company"), a medical technology company dedicated to improving the lives of patients with blinding eye diseases, today announced it has secured a new patent ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Dupilumab is being jointly developed by Sanofi and Regeneron under a global ... to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and ... will approach the end of its patent life.

Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration ... investigations relating to the Company and/or its operations (including the pending civil proceedings ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

Sanofi and Teva Pharmaceuticals ... risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease <li /> New detailed data from ...

And yes, we basically based it on what we think without having had any direct discussions from – with Sanofi ... patent extension application, if I remember it correctly, the application was ...